Asymmetry Capital Management, L.P. is an investment fund managing more than $55.8 million ran by Cindy Goldsmith. There are currently 33 companies in Mrs. Goldsmith’s portfolio. The largest investments include Baxter International and BioMarin Pharmaceutical, together worth $7.22 million.
As of 7th October 2020, Asymmetry Capital Management, L.P.’s top holding is 52,192 shares of Baxter International currently worth over $4.36 million and making up 7.8% of the portfolio value.
Relative to the number of outstanding shares of Baxter International, Asymmetry Capital Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 33,781 shares of BioMarin Pharmaceutical worth $2.86 million, whose value fell 6.8% in the past six months.
The third-largest holding is Centene worth $2.79 million and the next is Guardant Health worth $2.75 million, with 35,236 shares owned.
Currently, Asymmetry Capital Management, L.P.'s portfolio is worth at least $55.8 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Asymmetry Capital Management, L.P. office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Cindy Goldsmith serves as the CFO at Asymmetry Capital Management, L.P..
In the most recent 13F filing, Asymmetry Capital Management, L.P. revealed that it had opened a new position in
Baxter International and bought 52,192 shares worth $4.36 million.
This means they effectively own approximately 0.1% of the company.
Baxter International makes up
9.2%
of the fund's Health Care sector allocation and has decreased its share price by 8.1% in the past year.
The investment fund also strengthened its position in Tandem Diabetes Care by buying
24,564 additional shares.
This makes their stake in Tandem Diabetes Care total 43,559 shares worth $2.6 million.
Tandem Diabetes Care soared 115.0% in the past year.
On the other hand, there are companies that Asymmetry Capital Management, L.P. is getting rid of from its portfolio.
Asymmetry Capital Management, L.P. closed its position in Global Blood Therapeutics on 12th February 2020.
It sold the previously owned 75,011 shares for $3.64 million.
Cindy Goldsmith also disclosed a decreased stake in BioMarin Pharmaceutical by 0.3%.
This leaves the value of the investment at $2.86 million and 33,781 shares.
The two most similar investment funds to Asymmetry Capital Management, L.P. are Jd Capital Management and Signia Capital Management. They manage $55.7 million and $55.7 million respectively.
Asymmetry Capital Management, L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 85.4% of
the total portfolio value.
The fund focuses on investments in the United States as
81.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
27% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $26.6 billion.
These positions were updated on February 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Baxter International, Inc. |
Opened
52,192
|
$4,364,000 | 7.82% |
| Global Blood Therapeutics, Inc. |
Closed
75,011
|
$3,640,000 | |
| BioMarin Pharmaceutical, Inc. |
31.43%
33,781
|
$2,856,000 | 5.12% |
| Centene Corp. |
Opened
44,426
|
$2,793,000 | 5.01% |
| Guardant Health, Inc. |
Opened
35,236
|
$2,753,000 | 4.93% |
| Gw Pharmaceuticals -adr |
Closed
23,729
|
$2,730,000 | |
| Insmed, Inc. |
54.56%
113,875
|
$2,719,000 | 4.87% |
| Mylan NV |
Opened
132,855
|
$2,670,000 | 4.79% |
| PTC Therapeutics, Inc. |
54.00%
55,408
|
$2,661,000 | 4.77% |
| Tandem Diabetes Care, Inc. |
129.32%
43,559
|
$2,597,000 | 4.65% |
| Bio-rad Laboratories-a |
12.65%
6,351
|
$2,350,000 | 4.21% |
| DexCom, Inc. |
Closed
14,770
|
$2,204,000 | |
| Natera, Inc. |
Closed
63,112
|
$2,070,000 | |
| Arena Pharmaceuticals, Inc. |
162.34%
42,688
|
$1,939,000 | 3.48% |
| UnitedHealth Group, Inc. |
Opened
6,414
|
$1,886,000 | 3.38% |
| Acceleron Pharma, Inc. |
Closed
47,453
|
$1,875,000 | |
| Regeneron Pharmaceuticals, Inc. |
Opened
4,584
|
$1,721,000 | 3.08% |
| MyoKardia, Inc. |
51.94%
23,023
|
$1,678,000 | 3.01% |
| AbbVie, Inc. |
Opened
18,921
|
$1,675,000 | 3.00% |
| Amarin Corp Plc -adr |
Closed
104,509
|
$1,584,000 | |
| CRISPR Therapeutics AG |
Closed
37,141
|
$1,522,000 | |
| Aerie Pharmaceuticals, Inc. |
Opened
62,507
|
$1,511,000 | 2.71% |
| Dermira Inc |
Opened
81,127
|
$1,442,000 | 2.58% |
| Exicure, Inc. |
Opened
500,000
|
$1,430,000 | 2.56% |
| Esperion Therapeutics, Inc. |
Opened
22,872
|
$1,364,000 | 2.44% |
| Gilead Sciences, Inc. |
61.13%
20,791
|
$1,351,000 | 2.42% |
| Antares Pharma, Inc. |
Closed
377,399
|
$1,262,000 | |
| Bristol-myers Squibb-cvr |
Opened
415,931
|
$1,252,000 | 2.24% |
| Momenta Pharmaceuticals, Inc. |
Opened
62,585
|
$1,235,000 | 2.21% |
| eHealth, Inc. |
Opened
15,004
|
$1,230,000 | 2.20% |
| Portola Pharmaceuticals, Inc. |
67.11%
49,431
|
$1,180,000 | 2.12% |
| Twist Bioscience Corp. |
42.17%
54,334
|
$1,141,000 | 2.05% |
| Verrica Pharmaceuticals, Inc. |
Closed
74,301
|
$1,097,000 | |
| ViewRay, Inc. |
Opened
256,205
|
$1,081,000 | 1.94% |
| Nucana Plc-adr |
2.72%
159,898
|
$975,000 | 1.75% |
| Amicus Therapeutics, Inc. |
Opened
98,718
|
$962,000 | 1.72% |
| Ascendis Pharma A/s - Adr |
Opened
6,547
|
$911,000 | 1.63% |
| Cytokinetics, Inc. |
Opened
85,172
|
$904,000 | 1.62% |
| Mirati Therapeutics, Inc. |
Opened
6,950
|
$896,000 | 1.61% |
| Varian Medical Systems, Inc. |
Opened
5,934
|
$843,000 | 1.51% |
| Marinus Pharmaceuticals, Inc. |
Opened
354,853
|
$766,000 | 1.37% |
| Heron Therapeutics, Inc. |
Closed
39,273
|
$727,000 | |
| Apellis Pharmaceuticals, Inc. |
Opened
21,380
|
$655,000 | 1.17% |
| Penumbra, Inc. |
Closed
2,700
|
$363,000 | |
| No transactions found | |||
| Showing first 500 out of 44 holdings | |||